Apyx Medical posted another solid quarter, says Piper Jaffray

Piper Jaffray analyst Matt O’Brien says Apyx Medical posted another solid quarter in-line with its preannouncement, highlighted by “strong advanced energy growth off a tough comp.” While the company’s expense guidance may make the earnings outlook a little less favorable in the near-term, given the light penetration into this $1.5B market and the potential for several international expansions in 2019, its growth “should remain healthy for many years,” O’Brien tells investors in a research note. He encourages risk tolerant investors to own the name and reiterates an Overweight rating on Apyx Medical with a $10 price target.

https://thefly.com/landingPageNews.php?id=2878941